An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas

Trial Profile

An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs CX 072 (Primary) ; Ipilimumab (Primary) ; Vemurafenib (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms PROCLAIM-072
  • Sponsors CytomX Therapeutics
  • Most Recent Events

    • 07 Aug 2017 According to a CytomX Therapeutics media release, the patient enrollment has been initiated for CX-072 in combination with Yervoy (ipilimumab) and Zelboraf (vemurafenib) arms . Also, enrollment for monotherapy dose escalation arm is expected to be complete in second half 2017. An expansion cohort of this study, to evaluate CX-072 as monotherapy, is expect to begin enrolling patients in first half of 2018.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 17 May 2017 According to a CytomX Therapeutics media release, this study will be present at American Society for Clinical Oncology (ASCO) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top